Etorkizuneko farmako-menua: Burmuineko minbizidun haurrentzako medikuntza pertsonalizaturako plataforma aurreratua

Abstract

Brain tumours are the deadliest form of cancer in children, encompassing a heterogeneous group of diseases. Current standard-of-care is often ineffective, especially in poor prognosis subtypes. A major challenge for the translation of targeted drugs is intratumour heterogeneity, which drives therapeutic evasion and relapse. This work aims to establish a comprehensive platform for molecular and drug sensitivity profiling of pediatric brain cancers focusing on the phenotypic and functional characterization of treatment-resistant brain cancer stem cells. With this approach, we expect to find novel highly potent drug combinations that show long-term efficacy, supporting the clinical implementation of personalized medicines and improving survival of children with brain cancers.